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Abstract
Background: The potential contribution of vitamin D and its receptor (VDR) to bronchopulmonary dysplasia (BPD)
in preterm neonates is still unknown. The objective of the study was to test the relationship between VDR Taq 1
and Fok 1 gene polymorphisms and BPD in preterm neonates. VDR Fok 1 and Taq 1 gene polymorphisms were
genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis.
Result: No statistically significant differences of genotypic distributions and allele frequencies of Fok 1 and Taq 1
VDR polymorphisms were detected between cases and controls. Moreover, no risk association was detected
between both polymorphisms and BPD development in preterm neonates. Homozygous mutant (ff) genotype was
the least frequent genotype among BPD and non-BPD groups (2.6%, 13.0% respectively) (p = 0.1). The same was
detected for the mutant (CC) genotype frequency in both groups (10.5% and 15.2%, respectively). However, Taq 1
VDR polymorphism was significantly associated with the severity of BPD, as the genotypes with mutant allele C (CC
+CT) were more frequent among severe cases (52.2%).
Conclusion: Fok 1and Taq 1 VDR polymorphisms have no role in BPD development in preterm neonates. However,
the presence of a mutant allele of Taq 1 VDR polymorphism may be associated with a more severe form of the
disease.
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Background
Bronchopulmonary dysplasia (BPD) is a worldwide
major challenging consequence of prematurity and
has a significant heritability [1]. In the USA alone,
yearly reported new cases were about 10,000–15,000
[2]. Moreover, another study reported that BPD inci-
dence ranged from 20% in preterm infants up to 60%
in extremely preterm infants who were born before
26 weeks of gestation [3]. Although the major inflam-
matory role in the pathogenesis of BPD due to pre-
maturity and perinatal triggering factors has been
established, the genetic predisposition mechanisms re-
main unknown [4, 5]. According to twin studies, mo-
lecular factors represent about 53–82% of the
variance in predisposition to BPD [6, 7]. Bronchopul-
monary dysplasia is associated with future risk of re-
active airway disease [3], infant mortality, and
conflicting neurodevelopmental outcomes [8]. There
are limited therapies available to prevent BPD despite
recent advances, hence comes the role of genetic vari-
ants [2].
The effect of vitamin D on bone and mineral metabol-
ism has been well-known through the role of the vitamin
D receptor (VDR) that acts as a ligand-activated tran-
scription factor [9].
The VDR is expressed in numerous systems other than
skeletal, such as immune and respiratory systems [10].
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The effect of vitamin D on several morbidities, such as
multiple sclerosis, diabetes, and malignancies, has been
established through affecting immunity and cell prolifer-
ation [11].
Several researchers reported the important role of vita-
min D and its receptor in the pathogenesis of chronic
lung diseases through interactions between genes related
to cellular proliferation, differentiation, inflammation,
and immunity [12]. Furthermore, some studies reported
its important role as a regulator for intrauterine lung de-
velopment [13–15]. In animal studies, a low level of vita-
min D with pregnancy tends to modify alveolar
epithelial-mesenchymal signaling and reduce tracheal
width, thus increasing airway resistance and reducing
lung compliance, which results in lung hypofunction in
fetal mice [16]. Additionally, in human studies, the im-
pact of vitamin D on the production of pulmonary sur-
factant has been confirmed [17]. As it has an important
role as a growth factor for type-II alveolar pneumocytes,
local elaboration of VDR was considered an innovative
mechanism that may affect the epithelial growth of lung
development and modulation [18]. So, further studies
are still needed to assess the relationship between VDR
polymorphisms and BPD.
The aim of this study was to determine the possible
association between VDR Fok 1 and Taq 1 gene poly-




This case-control study included 84 newborns and was
carried out at the neonatal intensive care unit (NICU)
of Kasr AlAiny Hospitals, Cairo University, over a
period of 1 year, starting from December 2018 to No-
vember 2019.
Infants were recruited into the study if they had been
admitted to NICU and born prematurely with a gesta-
tional age of ≤ 32 weeks and a birth weight of ≤ 1500 g.
Newborns who fulfilled the criteria for the BPD diagno-
sis joined the case group (38 cases), while the matched
control group (46 cases) was selected among premature
cases that had been admitted to NICU for different pur-
poses but did not fulfill the criteria for the diagnosis of
BPD. A BPD diagnosis and severity were carried out de-
pending on the National Institute of Child Health and
Human Development (NICHD) severity-based definition
of BPD [19]. For those born at less than 32 weeks of ges-
tation, BPD was defined as the need for oxygen support
of more than 21% for at least 28 days and a subsequent
assessment at 36 weeks postmenstrual age or discharge.
In the case of those born with more than 32 weeks of
gestation, BPD was defined as the need for supplemental
oxygen of more than 21% for at least 28 days and a
subsequent assessment at 56 days postnatal age or dis-
charge. At the time of assessment, infants with no oxy-
gen need were considered as mild BPD. Moderate BPD
was considered in cases needing less than 30% oxygen,
while severe BPD was considered in cases with a need
for positive pressure and/or oxygen support of ≥30%
[19]. BPD risk factor-related data were collected from
medical records of both groups: gestational age, birth
weight, gender, mode of delivery, duration of mechanical
ventilation, duration of oxygen therapy, administration
of surfactant, presence of patent ductus arteriosus re-
quiring treatment, duration of hospitalization, and mor-
tality. Additionally, some prematurity-related
complications were taken into account. They included
respiratory distress syndrome (RDS) that was considered
in premature infants when they presented shortly after
birth with clinical signs of respiratory distress with the
need for supplemental oxygen (FiO2 >0.21) to achieve
oxygen saturation >90% and evidence of respiratory
acidemia in blood gasses (pH < 7.25 and PCO2> 60
mmHg) [20].
The typical radiological findings and grading of RDS
were considered in the chest x-ray of all cases: hypoex-
pansion and diffuse fine granular appearance (grade I),
air bronchogram caused by atelectasis of the alveoli
(grade II), ground-glass opacities (grade III), or white
lungs caused by diffuse bilateral atelectasis (grade IV)
[21]. Sepsis was diagnosed by a positive blood culture or
a positive C-reactive protein and the immature-to-total-
neutrophil ratio of more than 0.2 with concomitant clin-
ical signs of sepsis. Sepsis in the first three postnatal
days was defined as early-onset sepsis (EOS), while later
sepsis was defined as late-onset sepsis (LOS) [22]. Nec-
rotizing enterocolitis (NEC) was detected based on
modified Bell staging criteria [23], and cases with grade
Ib or more were considered. Intraventricular
hemorrhage (IVH) was diagnosed by cranial ultrasound,
and we only considered cases with grade II or more.
All newborns suspected of having genetic diseases or
congenital anomalies were excluded from both groups.
The study protocol was approved by the Ethics Commit-
tee of Faculty of Medicine, and it conformed to the pro-
visions of the Declaration of Helsinki of 1964 and its
later amendments or comparable ethical standards. An
informed written consent was obtained from parents/
surrogates of each child before enrollment in this study.
Methods
Detection of vitamin D receptor polymorphism using
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP)
Genomic DNA of included subjects was isolated from
ethylenediaminetetraacetic acid (EDTA)-treated whole
blood, using a G-spin TM total DNA extraction kit
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(iNtRON Biotechnology, Korea). Genotyping of vitamin
D receptor polymorphism (Fok1 and Taq1 sites) was
performed using the PCR-RFLP technique. The primer
sequences used were as follows: for Fok 1 polymorphism,
forward primer: 5′-AGCTGGCCCTGGCACTGACTCT
GCTCT-3′, reverse primer: 5′ATGGAAA-
CACCTTGCTTCTTCTCCCTC-3′ [24], while for the
Taq1 polymorphism, forward primer: 5′-CAG AGC
ATG GAC AGG GAG CAAG-3′, reverse primer: 5′-
GCAACT CCTCATGGCTGAGGTCTCA-3′ [25]. Amp-
lification was done using 2X PCR Master mix Solution
(iTaqTM) (iNtRON biotechnology, Korea) in a total vol-
ume of 20μl.
For Fok 1 polymorphism amplification, an initial
denaturation at 95 °C for 3 min was followed by 35
cycles consisting of 30 s of denaturation at 94 °C,
30 s of annealing at 60 °C, and an extension for 30
s at 72 °C, and then, a final extension at 72 °C for 5
min. For Taq 1 polymorphism amplification, an ini-
tial denaturation at 95 °C for 3 min was followed by
35 cycles consisting of 45 s of denaturation at 93
°C, 30 s of annealing at 66 °C, and an extension for
45 s at 72 °C and then a final extension at 72 °C
for 5 min.
Amplification products were subjected to restriction
digestion by the enzyme Fok 1 (Enzynomics, Korea)
and Taq 1 (Enzynomics, Korea), respectively. Frag-
ments were separated on 2% agarose gel, and bands
were visualized by ethidium bromide staining under
ultraviolet (UV) light. Fok 1 reaction yielded one frag-
ment of 265 bp indicating homozygous wild genotype
(FF) (Fig. 1); Taq 1 reaction yielded two fragments of
495 bp and 245 bp indicating a homozygous wild
genotype (FF) (Fig. 2).
Sample size
Sample size calculation was performed using the Power
and Sample Size Calculation program version 3.0.43. It
was based on the following inputs: the power of 90%,
type 1 error 0.05, an equal number of candidates in both
cases and controls, true difference in mean between
groups 0.9, and a standard deviation 3.8. Thirty-eight
subjects were found in each group.
Statistical methods
The data was analyzed using Microsoft Excel 2010
and a statistical package for social science (SPSS ver-
sion 24.0) for Windows (SPSS IBM., Chicago, IL).
Continuous normally distributed variables were pre-
sented as mean ± SD with a 95% confidence interval
using the frequencies and percentage for categorical
variables; a p value < 0.05 was considered statisti-
cally significant. To compare the means of normally
distributed variables between groups, Student’s t-test
was performed. χ2 test or Fisher’s exact test was
used to determine the distribution of categorical var-
iables between groups. Haplotype analysis was done
using the haplotype analysis software v1.05. The sta-
tus of Hardy–Weinberg equilibrium (HWE) was
checked through the analysis of genotype distribu-
tion. Effect modifications were evaluated by stratifi-
cation; statistical interaction was assessed by
including main effect variables and their product
Fig. 1 Vitamin D receptor gene polymorphism (Fok 1). Lanes 1, 3, 4,
and 7: homozygous wild FF genotype (265 bp). Lanes 2 and 5:
heterozygous genotype Ff (265 bp, 196 bp, and 69 bp). Lane 6:
homozygous mutant ff genotype (196 bp and 69 bp). Lane 8: 100bp
DNA Ladder (100, 200, 300, 400, 500,600,700,800, 900, 1000, 1500 bp)
Fig. 2 Vitamin D receptor gene polymorphism (Taq 1). Lane 1:
homozygous mutant CC genotype (290bp, 245bp and 205 bp). Lane
2: homozygous wild TT genotype (495 bp and 245bp). Lanes 3,4 and
5: heterozygous genotype TC (495bp, 290bp, 245bp and 205 bp).
Lane 8: 50 bp DNA Ladder (50,100,150,200,250,300,400,500, 600,700,
800, 900, 1000 bp)
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terms in the multiple stepwise backward logistic re-
gression model.
Results
Clinical and demographic data
The study involved 84 preterm neonates, in which 38
patients were diagnosed as BPD and 46 without BPD.
The BPD group comprised 16 males (42.1%) and 22 fe-
males (57.9%); their mean age ± SD was 30 ± 1.5 weeks.
While the non-BPD group comprised 24 males (52.2%)
and 22 females (47.8%), their mean age ± SD was 31 ±
1.3 weeks. Among the control group, 32 (69.6%) cases
were less than 30 weeks, while, among the cases, 15
(39.5%) were less than 30 weeks.
Antenatal variables were comparable between BPD and
non-BPD groups with no significant differences, except
for gestational age, as the BPD group has significantly
lower age. On the other hand, BPD cases required more
frequent O2 supply, mechanical ventilation (MV), and ino-
tropic support (p< 0.001), and they were admitted for lon-
ger periods in comparison to the non-BPD group.
The BPD cases were classified according to the sever-
ity of the disease into three groups: mild cases 4 (10.6%),
moderate cases 17 (44.7%), and severe cases 17 (44.7%).
No significant statistical difference in disease severity be-
tween BPD cases was found with an age of fewer than
30 weeks versus those aged 30 weeks or more. Among
those with 30 or more weeks, three mild, eleven moder-
ate, and nine severe cases were observed versus one
mild, six moderate, and eight severe cases in patients less
than 30 weeks (p value 0.642).
Hemodynamically, the BPD group showed significant
patent ductus arteriosus (PDA) in 23 cases (60.5%) in
comparison to the 11 cases in the non-BPD group
(23.9%) (p=0.01). Regarding the occurrence of neonatal
sepsis, late-onset neonatal sepsis was more frequent in
the BPD group than the non-BPD group. All demo-
graphic and clinical data are shown in Table 1.
Fok 1 and Taq 1 VDR polymorphism results
The controls and BPD cases fit in the Hardy-Weinberg
equilibrium for both Fok1 and Taq1 genotypes and have
a p value > 0.05.
Regarding Fok 1 VDR polymorphism genotypic distri-
bution (FF, Ff, ff), no significant statistical difference was
detected between the studied groups (p value >0.05);
homozygous mutant (ff) genotype was the least frequent
genotype among BPD and non-BPD groups (2.6%, 13.0%
respectively) (p value 0.1). Moreover, the allelic distribu-
tions of F and f alleles did not differ significantly be-
tween the cases and the controls (p value >0.05).
Regarding Taq 1 genotype distribution, the difference
in genotypic distribution (TT, TC, CC) was not statisti-
cally significant between the cases and the controls (p
value >0.05); the homozygous mutant (CC) genotype fre-
quency was the least frequent genotype in BPD and
non-BPD groups (10.5% and 15.2% respectively). Fur-
thermore, there was no statistical difference between the
allelic distributions (T allele, C allele) in the studied
groups where the mutant (C) allele frequencies were
27% and 35% in patients and control groups, respect-
ively, (p = 0.7).
Wild genotypes and wild alleles of both Fok 1 and Taq
1 VDR polymorphisms were taken as references for the
risk assessment, and analysis revealed no significant as-
sociation between both polymorphisms and the risk of
BPD in our preterm neonates (Table 2). Moreover, no
risk association between both polymorphisms and BPD
development when cases are more stratified according to
gestational age (≥30 weeks and <30 weeks) (Table 3).
Haplotype association analysis revealed no significant
differences between the cases and the controls regarding
the frequency of different haplotypes (Table 4).
Taq 1 VDR polymorphism was significantly associated
with the severity of BPD as the genotypes with mutant
allele C (CC +CT) were more frequent among severe
cases (52.2%). But such association was not detected for
Fok 1 VDR polymorphism (Table 5).
No associations were detected between Taq 1 and Fok
1 VDR polymorphism genotypes and the disease out-
come among preterm newborns (Table 5).
Risk assessment for the development of BPD
In studying the univariate analysis of potential clinical risk
factors for the development of BPD, gestational age, dur-
ation of hospitalization, administration of O2, and mechan-
ical ventilation together with inotropes and surfactant had a
potential effect on the development of BPD. Moreover,
late-onset sepsis, PDA, pneumothorax, IVH, and NEC were
associated with an increased risk of BPD (Table 6).
Multiple stepwise backward logistic regression was
conducted to find the significant predictors for grouping
(control/case). The independent variables entered on
step 1 are Taq1, Fok1 VDR gene polymorphisms, gesta-
tional age, late-onset neonatal sepsis, PDA, Apgar at 5
min, and RDS grade depending on chest x-ray findings.
The model was significant X2 (49.27) and p value <
0.001. It can independently explain the change in the
grouping by 44.4% (r2 0.444). The significant predictors
in the model were RDS severity and Apgar at 5 min,
which means that an increase in the severity of RDS is
more significantly associated with BPD cases than with
the controls (p<0.001, OR 9.98, 95% CI 3.2–31.12). Every
unit increase in Apgar score at 5 min increases the prob-
ability of the patient not having a disease (control) (p
0.002, OR 0.49, 95% CI 0.32–0.77), * P value <0.05 is sig-
nificant, while **P value < 0.01 is highly significant.
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Table 1 Demographic and clinical data
Non-BPD, N= 46 BPD, N= 38 p value
Gestational age 31±1.3 30±1.5 0.003
Gender
Male 24 (52.2%) 16 (42.1%) 0.5
Mode of delivery
CS 36 (78.3%) 30 (78.9%) 0.9
VD 10 (21.7%) 8 (21.1%) 0.9
Birth weight (g) 1350.43±24.66 1298.79±38.97 0.2
History of PROM
Yes 11 (23.9%) 11 (28.9%) 0.7
Antenatal steroid
Yes 17 (37.0%) 13 (34.2%) 0.8
Multiple gestation
Yes 10 (21.7%) 6 (15.8%) 0.5
Preeclampsia
Yes 6 (13%) 7 (18.4%) 0.16
Duration of admission (days)
Mean ± SD 32.67±1.68 55.21±2.95 0.001
Duration of O2 (days) 12.91±0.93 44.11±3.0 0.001
Mechanical ventilation
Yes 7 (15.2%) 33 (86.8%) 0.001
MV duration 0.46±0.17 25.63±2.63 0.001
Apgar at 1 min
Mean±SD 4.9+1.9 2.6+1.2 0.01
Apgar at 5 min
Mean±SD 6.7±1.47 5.2±1.1 0.01
Inhaled steroid duration (days) 6.57±0.89 31.87±3.35 0.001
Intake of inotropes
Yes 18 (39.1%) 38 (100.0%) 0.001
Inotropes duration (days) 2.87±0.61 16.47±1.51 0.001
Onset of trophic feeding (days) 2.35±0.08 3.29±0.36 0.01
TPN
Yes 43 (93.5%) 38 (100.0%) 0.7
Duration of TPN (days) 13.85±1.09 31.74±1.68 0.001
Patent ductus arteriosus 11 (23.9%) 23 (60.5%) 0.001
Early onset sepsis 19 (51.4%) 18 (48.6%) 0.3
Late onset sepsis 33 (47.1%) 37 (52.9%) 0.01
Admission chest X-ray
Normal 2 (4.3%) 0 (0.0%) 0.2
Mild RDS 34 (73.9%) 8 (21.1%) 0.001
Moderate RDS 5 (10.9%) 7 (18.4%) 0.3
Severe RDS 5 (10.9%) 23 (60.5%) 0.001
Pneumothorax
Yes 1 (2.2%) 25 (65.8%) 0.001
IVH
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Discussion
BPD is a relevant chronic lung disease attributed to pre-
maturity. Various studies considered the genetic aberra-
tions involved in the development of BPD and were not
conclusive. However, they highlighted several genes, var-
iants, and pathways involved in the susceptibility to BPD
[26].
The gene encoding the VDR is placed on chromo-
some 12; it contains 11 exons and 75 kb spans of
genomic DNA [27]. There are more than two hun-
dred polymorphisms of the VDR gene. The most de-
scribed were Fok 1, Bsm 1, Apa 1, and Taq 1
polymorphisms. The Fok 1 is in exon 2 and results in
the construction of a longer and less active protein,
while Bsm1, Apa1, and Taq1 polymorphisms are lo-
cated between exons 8 and 9 [24].
Taq 1 polymorphism is located at the untranslated re-
gion (UTR) of the VDR gene, which has an important
role in the regulation of mRNA stability and protein
translation, and thus the altered VDR levels may affect
vitamin D signaling [28].
The current study revealed that neither Fok 1 nor Taq
1 was associated with susceptibility to BPD in Egyptian
neonates. Moreover, the allelic distribution of F and f al-
leles, on the one hand, and T and C alleles, on the other
hand, respectively, was similar in both groups. To the
best of our knowledge, Koroglu et al. [29] was the only
study that evaluated possible associations of both poly-
morphisms and BPD. It reported a significant association
of mutant Fok1 genotype as a risk factor for the develop-
ment of BPD (detected in 53.1% of the cases versus
33.9% in the control group); furthermore, the mutant
Table 1 Demographic and clinical data (Continued)
Non-BPD, N= 46 BPD, N= 38 p value
Yes 9 (19.6%) 23 (60.5%) 0.001
Necrotizing enterocolitis
Yes 6 (13.0%) 15 (39.5%) 0.02
Jaundice
Yes 32 (69.6%) 32 (84.2%) 0.4
Intake of surfactant
Yes 7 (15.2%) 18 (47.4%) 0.01
Outcome
Died 3 (6.5%) 12 (31.6%) 0.01
Living 43 (93.5%) 26 (68.4%) 0.001
CS cesarean section, VD vaginal delivery, PROM premature rapture of membrane, MV mechanical ventilation, TPN total parenteral nutrition, RDS respiratory distress
syndrome, IVH, intraventricular hemorrhage
Table 2 Genotypic distribution and allelic frequencies of Taq 1 and Fok 1 VDR polymorphisms
Non-BPD (N=46), No. (%) BPD (N=38), No. (%) 1p value Odds ratio 95% CI
Fok1 VDR gene polymorphism
FF 26 (56.5%) 20 (52.6%) 0.8 1
Ff 14 (30.4%) 17 (44.7%) 0.3 1.579 0.631–3.948
ff 6 (13.0%) 1 (2.6%) 0.1 2.500 0.024–1.947
Ff+ff 20 (43.5%) 18 (47.4%) 0.7 1.170 0.493–2.774
F allele 66 (71.7%) 57 (75%) 0.8 1
f allele 26 (28.3%) 19 (25%) 0.6 0.846 0.425–1.686
Taq1 VDR gene polymorphism
TT 18 (39.1%) 15 (39.5%) - 1
TC 21 (45.7%) 19 (50.0%) 0.8 1.086 0.431–2.737
CC 7 (15.2%) 4 (10.5%) 0.6 0.686 0.168–2.799
TC+CC 28 (60.9%) 23 (60.5%) 0.9 0.986 0.409–2.376
T allele 57 (62%) 49 (64.5%) 0 1
C allele 35 (38%) 27 (35%) 0.7 0.897 0.478–1.686
1p value less than 0.05 is statistically significant
CI confidence interval
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genotype of Taq 1 VDR polymorphism was considered
to have a protective effect against BPD (detected in
12.8% of the cases versus 25.8% in the control group).
However, in their study, after controlling the gestational
age and birth weight variables, Fok1 polymorphism did
not have a significant effect on BPD susceptibility. Con-
trary to their results, our study of the Egyptian preterm
neonates revealed a low frequency of the mutant geno-
type of Fok1 (2.6% in BPD cases, 13% in non-BPD cases)
and mutant genotype of Taq1 polymorphism (10.5% in
BPD cases, 15.2% in non-BPD cases). These frequencies
of different expressions could be attributed to different
ethnicity, as was suggested by previous studies [30, 31].
The inconsistencies between studies expressing genetic
risks may be due to genetic heterogeneity, gene-to-
environment and/or gene-to-gene interactions, as well as
population admixture [32].
The present study revealed that mutant genotypes
(CC+CT) of Taq 1 VDR polymorphism were signifi-
cantly more frequent among severe cases of BPD; this
finding was not detected for Fok1 polymorphism. Al-
though Taq 1 polymorphism is nonfunctional, it shares
other functional polymorphisms and a complex gene
network affecting the expression of the VDR gene, and
this could explain its relation to the severity of the dis-
ease [28]. Vitamin D and VDR may also play a role in
the pathogenesis of chronic lung diseases through epi-
genetic control of the inflammatory process, immune
regulation, and cellular proliferation [12]. Moreover,
VDR receptor polymorphism may contribute to a higher
incidence of respiratory tract infections through their ef-
fects on innate immunity [33]. Alongside all these fac-
tors that may explain the link between VDR
Table 3 Genotypic distribution of Taq 1 and Fok 1 VDR polymorphisms among different age groups
Non-BPD (N=14 ), No. (%) BPD (N=23), No. (%) 1p value Odds ratio 95% CI
Age >30
Fok1 VDR gene polymorphism
FF 7 (50%) 13 (56.5%) - 1
Ff+ff 7 (50%) 10 (43.5%) 0.6997 0.769 0.202–2.917
Taq1 VDR gene polymorphism
TT 7 (50%) 9 (39.1%) - 1
TC+CC 7 (50%) 14 (60.2%) 0.518 1.555 0.406–5.947
Non-BPD (N=32), No. (%) BPD (N=15), No. (%) 1p value Odds ratio 95% CI
Age <30
Fok1 VDR gene polymorphism
FF 19 (59.4%) 7 (46.7%) - 1
Ff+ff 13 (40.6%) 8 (53.3%) 0.415 1.670 0.485–5.746
Taq1 VDR gene polymorphism
TT 11 (34.4%) 6 (40%) - 1
TC+CC 21 (65.5%) 9 (60%) 0.708 0.785 0.222–2.782
1p value less than 0.05 is statistically significant
CI confidence interval
Table 4 Combined Taq1 and Fok1 haplotype frequencies
among cases and controls
Haplotype Non-BPD BPD p value
N % N %
FT 42 45.7% 43 56.6% 0.3
FC 15 16.3% 6 7.9% 0.1
fT 24 26.1% 14 18.4% 0.3
fC 11 12.0% 13 17.1% 0.4
Table 5 The association between Taq 1 and Fok 1 VDR
polymorphism genotypes and both the outcome and disease
severity among BPD cases
Variable Taq1 VDR genotyping p value
TT TC+CC
Outcome Died 4 (26.7%) 8 (34.8%) 0.6
Living 11 (73.3%) 15 (65.2%)
Severity of BPD Mild 3 (20.0%) 1 (4.3%) 0.02
Moderate 7 (46.7%) 10 (43.5%)
Severe 5 (33.3%) 12 (52.2%)
Fok1 VDR genotypes
FF Ff+ff
Outcome Died 8 (40.0%) 4(22.2%) 0.1
Living 12 (60.0%) 14(77.8%)
Severity of BPD Mild 1 (5.0%) 3(16.7%) 0.5
Moderate 8 (40.0%) 9(50.0%)
Severe 11 (55.0%) 6(33.3%)
BPD bronchopulmonary dysplasia
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polymorphism, vitamin D axis, and severity of BPD,
there are several studies that have recognized a relation-
ship between low serum vitamin D level [34], vitamin D
binding protein (Gc globulin) [35], and subsequent risk
of BPD development.
The current study revealed significant associations be-
tween some clinical factors and the risk of BPD, such as
lower gestational age, long duration of oxygen therapy,
mechanical ventilation, significant PDA, late-onset sep-
sis, severe RDS, surfactant therapy, and long admission
duration. These findings were in agreement with several
other studies [29, 36, 37]. Our study also showed that
BPD cases were significantly associated with NEC, IVH
similarly to Landry et al. [38]. And Mailaparambil et al.
[39] concluded that BPD was more associated with some
clinical factors rather than genetic polymorphisms.
Moreover, some researchers explored the relationships
between Fok 1 and Taq polymorphisms and the develop-
ment of these BPD-related risk factors in premature ba-
bies, as Ustun et al. [40] suggested that Taq1
polymorphism may be considered as a risk factor of RDS,
while Mokhtar et al. [41] revealed a significant association
of Fok 1 polymorphism and neonatal sepsis whereas
Barchitta et al. [42] revealed a significant role of Fok 1
polymorphism with gestational duration and birth weight.
The study limitations here could be attributed to the
relatively small sample size enrolled in the study, as well
as a single tertiary center experience; thus, further studies
with larger cohorts are recommended to confirm the role
of these SNPs as molecular incriminators to the addressed
pathology. Likewise, 25 (OH) D serum levels should have
been examined in order to study the link between the
studied genetic polymorphisms and its serum levels.
Conclusion
Our findings revealed that neither the Fok 1 nor the Taq
1 were associated with an increased risk of BPD. More-
over, the mutant variants of both polymorphisms are de-
tected at a low frequency among Egyptian preterm
neonates. The mutant genotypes (CC+CT) of Taq 1
VDR polymorphism were significantly more frequent
among severe cases of BPD. Further studies on a larger
group of preterm neonates and more genome-wide asso-
ciation studies are required to eradicate the inconsisten-
cies found so far and to elucidate the role of VDR
polymorphisms in relation to susceptibility to BPD and
its severity.
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